The short version of melanotan-2 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-18 and is reviewed periodically as new material appears.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Chick-fil-A's business strategy involves a focus on a small menu and on customer service. While many fast food chains offer many dishes, Chick-fil-A's is focused on selling chicken sandwiches. The name's capital A is intended to indicate that their chicken is "grade A top quality". The company's emphasis on customer service is reported to have contributed to its success and growth in the United States. Chick-fil-A builds and owns its restaurants. Chick-fil-A franchisees need a US$10,000 initial investment. Franchisees are selected and trained, a process that can take months. Chick-fil-A grossed an average of $6.71 million per restaurant in 2022, despite opening only 6 days a week, the highest sales of all fast-food restaurants in the United States. (Raising Cane's was second with $5.44 million per restaurant average). In 2019, Chick-fil-A reported $11.3 billion in sales in the United States, behind only McDonald's with $40.4 billion in sales that year. To compete with Chick-fil-A, the fried chicken chain Popeyes, followed by others, introduced a fried chicken sandwich in 2019, a marketing trend known as the chicken sandwich wars.
== External links == Professor Wickramasinghe's profile at the University of Buckingham Interviews Publication List Chandra Wickramasinghe@ Astrophysics Data System Prof Chandra Wickramasinghe in conversation with artist and poet, Himali Singh Soin, podcast, 2022
After testing the insulin on rabbits for more than a year, Eva was running out of conventional insulin and cautiously tried it on herself-–and it worked. In the Jewish ghetto where they were living, many other people with type 1 diabetes were also in dire need of insulin. Eva gave her insulin to two boys in a nearby hospital who were in diabetic comas. With a successful batch of homemade insulin, the Saxls began production of insulin for all people with Type 1 diabetes in the Shanghai Ghetto. In all, over 200 people survived between 1941 and 1945 and there were no fatalities reported as a result of tainted insulin. The Saxls left Shanghai after World War II and emigrated to the United States. Eva and Elliott P. Joslin, MD, founder of today's Joslin Diabetes Center in Boston, Massachusetts, befriended each other, and soon Dr. Joslin began inviting Eva to give lectures to groups of children and diabetes organizations. She became the first vocal spokesperson for Type 1 diabetes. Her husband worked for the United Nations.
Sources: en.wikipedia.org
He continued to perform in London, and in 1914 took part in the inaugural theatre performance held within the new ocean liner, RMS Aquitania, before its first sailing from Liverpool. Gammon died in Maida Vale, London, in June 1915, aged 48.
Robert Boyle improved Guericke's design and conducted experiments on the properties of vacuum. Robert Hooke also helped Boyle produce an air pump that helped to produce the vacuum. By 1709, Francis Hauksbee improved on the design further with his two-cylinder pump, where two pistons worked via a rack-and-pinion design that reportedly "gave a vacuum within about one inch of mercury of perfect." This design remained popular and only slightly changed until well into the nineteenth century.
insulin and IGF-1 driven proliferation of keratinocytes and fibroblasts fibroblast growth factor receptor abnormalities in hereditary forms transforming growth factor-α overexpression in malignancy-associated cases, activating the epidermal growth factor receptor Sweat, friction and occlusion may accentuate lesion development in predisposed areas.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.